Identification
- Summary
Riltozinameran is a component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1.
- Generic Name
- Riltozinameran
- DrugBank Accession Number
- DB17095
- Background
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021.2 It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta).3 As of November 2022, it is the primary circulating variant of concern according to the World Health Organization.2 The Omicron variant comprises several distinct lineages and sublineages (e.g. BA.4, BA.5) which, although similar, may behave differently from one another.3
Riltozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineage BA.1. It is administered in combination with tozinameran for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.11
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Not Available
- External IDs
- BNT162B2_B.1.1.529
Pharmacology
- Indication
Riltozinameran, in combination with tozinameran (Comirnaty Original / Omicron BA.1), is indicated in patients ≥12 years of age as a booster dose for active immunization against COVID-19 caused by SARS-CoV-2.1 It may be given 3 to 6 months after completion of a primary course of Comirnaty and/or a previous booster dose of Comirnaty.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Novel coronavirus infectious disease (covid-19) Combination Product in combination with: Tozinameran (DB15696) •••••••••••• •••••••••• •••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Riltozinameran is a nucleoside-modified mRNA encapsulated in lipid nanoparticles that facilitate the delivery of the mRNA into human cells.1 Once inside the host cells, the mRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein - specifically the S protein of the Omicron BA.1 variant lineage - which is subsequently recognized by the host immune system. Both neutralizing antibody and cellular immune responses are elicited in response to the vaccine, which helps protect against SARS-CoV-2 infection.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
There are no data regarding overdose with riltozinameran. In the event of a suspected overdose, monitoring of vital functions and symptomatic treatment is recommended.1
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Comirnaty Original/omicron Ba.1 Riltozinameran (15 mcg / 0.3 mL) + Tozinameran (15 mcg / 0.3 mL) Suspension Intramuscular Biontech Manufacturing Gmbh Not applicable Not applicable Canada 
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 72JR7XDV94
- CAS number
- 2749948-25-0
References
- General References
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Not Yet Recruiting Prevention Coronavirus Disease 2019 (COVID‑19) / Vaccines 1 Not Available Active Not Recruiting Not Available Anesthetics Adverse Reaction / Coronavirus Disease 2019 (COVID‑19) / Safety / Vaccines 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Intramuscular - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at November 09, 2022 16:56 / Updated at March 11, 2023 21:11